The Levofloxacin Sodium Chloride Injection independently researched and developed by Qidu Pharma is the first in China to be approved for marketing.Its drug approval number is H20203476 and H20203477.

The product has two packaging forms: PP Bag (Upright) and PVC-Free Soft Bag and two specifications for each packaging form: 50ml:0.25g and 100ml:0.5g. The product is applied in accordance with the new category 4 of China's National Drug Registration and classification system, and shall be regarded as having passed the consistency evaluation.

The advantages of the product:

The molecule does not contain chlorine ions, which effectively reduces the risk of hyperchloremia.

EDTA and activated carbon are not introduced in the production process to reduce adverse reactions.

Category-4 new drug shall be regarded as having passed the consistency evaluation.

Pharmacological property:

Levofloxacin, a new quinolone antibacterial drug, plays an antibacterial role by inhibiting the activity of bacterial DNA rotation enzyme and inhibiting the replication of bacterial DNA. With pharmacodynamic and pharmacokinetic characteristics, such as wide antimicrobial spectrum, strong sterilization effect, high blood drug concentration, wide distribution, high bioavailability, it has strong antibacterial activity for the majority of enterobacteriaceae bacteria, such as pneumonia, Klebsiella pneumoniae, Proteus, Salmonella typhi, Shigella, some Escherichia coli, etc and good antibacterial effect for some staphylococcus aureus, streptococcus pneumonia, flu bacilli, pseudomonas aeruginosa, neisseria gonorrhoeae, chlamydia, etc. It is suitable for the treatment or prevention of moderate and severe infections of respiratory system, urinary system, reproductive system, skin and soft tissue and intestinal tract caused by sensitive bacteria that have been proved or highly suspected. It is the most widely used antibacterial drug at home and abroad.